Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
5Activity
0 of .
Results for:
No results containing your search query
P. 1
Florinef (fludrocortisone)

Florinef (fludrocortisone)

Ratings:

4.0

(1)
|Views: 2,036|Likes:
Published by E

More info:

Published by: E on Oct 20, 2008
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as DOC, PDF, TXT or read online from Scribd
See more
See less

10/24/2012

pdf

text

original

 
Clinical Medications Worksheets
Generic Name
fludrocortisone
Trade Name
Florinef 
Classification
Hormones, corticosteroids (mineralocorticoid)
Dose
0.05 mg
Route
PO
Time/frequency
qd
Peak 
unknown
Onset
unknown
Duration
1-2 day
Normal dosage range
100mcg/day (range 100 mcg 3 times weekly – 200mcg daily). Dosesas small as 50 mcg daily may be required by some patients. Use with10-37.5 mg cortisone daily or 10-30 mg hydrocortisone daily.
Why is your patient getting this medication
Sodium loss and hypotension associated with adenocorticalinsufficiency (given with hydrocortisone or cortisone).
For IV meds, compatibility with IV drips and/or solutions
 N/A
Mechanism of action and indications
(Why med ordered)
Fludrocortisone binds the mineralocorticoid receptor (aldosterone receptor). This binding (or activation of themineralocorticoid receptor by fludrocortisone) in turn causesan increase in ion and water transport and thus raisesextracellular fluid volume and blood pressure and lowers potassium levels.
Nursing Implications (what to focus on)
Contraindications/warnings/interactions
CHF; Addison’s disease (patients may have exaggerated response)
Common side effects
CHF
Florinef (fludrocortisones)
 
Interactions with other patient drugs, OTC or herbalmedicines
(ask patient specifically)
Levaquin
: Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associatedwith fluoroquinolone treatment. The mechanism is unknown.Tendinitis and tendon rupture have most frequently involvedthe Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resultedin prolonged disability. Tendon rupture can occur during or upto several months after completion of fluoroquinolone therapy.
Miralax
: The overuse or abuse of laxatives can causesignificant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.Corticosteroids promote the retention of sodium and water andthe excretion of potassium. Although these effects are primarilyassociated with mineralocorticoids like fludrocortisone, theymay also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemicallyfor longer than brief periods.
Lanoxin
: Systemically administered corticosteroids mayinduce hypokalemia and possibly increase the risk of digoxintoxicity. In addition, corticosteroid-induced sodium and water retention can result in edema leading to heart failure. Theseeffects may be more common with the natural corticosteroids(cortisone, hydrocortisone) which have greater mineralocorticoid activity.
ASA
: Coadministration with corticosteroids may decrease theserum concentrations and therapeutic effects of salicylates.Likewise, serum salicylate levels may increase followingwithdrawal of corticosteroid therapy, potentially resulting insalicylate toxicity. This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.One or more mechanisms may be involved, including anincrease in the renal clearance and/or an induction of hepaticmetabolism of salicylates caused by corticosteroids.Pharmacologically, the potential for increased gastrointestinal(GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogeniceffects of these agents (especially aspirin) on the GI mucosa.
Grapefruit
: Grapefruit juice may increase the plasmaconcentrations of some orally administered drugs that aresubstrates of the CYP450 3A4 isoenzyme. The proposedmechanism is inhibition of CYP450 3A4-mediated first-passmetabolism in the gut wall by certain compounds present ingrapefruits. The extent and clinical significance are unknown.Moreover, pharmacokinetic alterations associated withinteractions involving grapefruit juice are often subject to ahigh degree of interpatient variability.
Lab value alterations caused by medicine
Monitor serum electrolytes periodically during therapy.Fludrocortisone causes decrease in serum potassium levels.
Be sure to teach the patient the following about this medication
Instruct patient to take medication as directed. Take missed doses assoon as remembered but not just before next dose is due. Explain thatlifelong therapy may be necessary and that abrupt discontinuation maylead to addisonian crisis. Patient should keep an adequate supplyavailable at all times. Advise patient to follow dietary modification prescribed by health care professional. Instruct patient to follow a diethigh in potassium. Amount of sodium allowed in diet varies with pathophysiology. Instruct patient to inform health care provider if weight gain or edema, muscle weakness, cramps, nausea, anorexia, or dizziness occurs. Advise patient to carry identification at all timesdescribing disease process and medication regimen.
Florinef (fludrocortisones)

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->